Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 32, No. 3, 2002
Issue release date: October 2002
Section title: Original Paper
Pathophysiol Haemost Thromb 2002;32:131–133

Prospective Assessment of a Nomogram for the Initiation of Oral Anticoagulation Therapy for Outpatient Treatment of Venous Thromboembolism

Kovacs M.J.a · Anderson D.A.b · Wells P.S.c
aDepartments of Medicine,aLondon Health Sciences Centre, London, Ontario, bQueen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, cOttawa Civic Hospital, Ottawa, Ontario, Canada
email Corresponding Author

Dr. Michael J. Kovacs

Room 2760, Phase 1, London Health Sciences Centre

800 Commissioners Road East

London, Ontario N6A 4G5 (Canada)

Tel. +1 519 685 8475, Fax +1 519 685 8477, E-Mail michael.kovacs@lhsc.on.ca

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Venous thromboembolism is a common medical problem. Recently, the emphasis has been on a switch to outpatient low molecular weight heparin therapy. Previous warfarin nomograms have been developed only for inpatients. We prospectively assessed a warfarin initiation nomogram in 105 consecutive outpatients; the nomogram requires International Normalized Ratio (INR) testing on only days 3, 5, and 8. Eighty-three percent had a therapeutic INR by day 5 and 98% by day 8. There were no major bleeds and only 6 instances of INR >4.5. This outpatient warfarin nomogram appears to be safe and efficacious in obtaining timely therapeutic levels of warfarin and deserves further study.

© 2002 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 10, 2001
Accepted: June 20, 2002
Published online: October 03, 2002
Issue release date: October 2002

Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: http://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.